Valuation: Lundbeck

Market Cap 54.63B 8.15B 7.31B 6.68B 6.1B 11.49B 766B 11.85B 80.5B 32.1B 409B 30.58B 29.93B 1,290B P/E 2026 *
12.1x
P/E 2027 * 12x
Enterprise Value 58.57B 8.73B 7.83B 7.16B 6.54B 12.31B 821B 12.7B 86.3B 34.41B 438B 32.78B 32.08B 1,383B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 2.07x
Free-Float
30.74%
Yield 2026 *
2.8%
Yield 2027 * 2.47%
1 day+2.62%
1 week+5.85%
Current month+5.00%
1 month+19.86%
3 months+46.85%
6 months+51.08%
Current year+45.03%
1 week 49.05
Extreme 49.05
52.9
1 month 43.8
Extreme 43.8
52.9
Current year 31.4
Extreme 31.4
52.9
1 year 31.4
Extreme 31.4
52.9
3 years 23.3
Extreme 23.3
52.9
5 years 21.94
Extreme 21.935
52.9
10 years 21.94
Extreme 21.935
52.9
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 67 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
+1.74%+5.85% - - 8.15B
-0.79%-4.48%+46.48%+118.69% 1,206B
+1.43%+1.11%+48.05%+83.72% 665B
+1.07%-1.21%+32.92%+105.10% 515B
+1.68%+0.05%+42.49%+66.90% 381B
-0.14%-1.87%+70.06%+40.55% 362B
+0.89%+2.30%+31.64%+59.60% 307B
+1.28%+2.11%+7.82%+35.61% 289B
+0.03%-1.20%+43.79%+68.49% 249B
-0.41%-2.22%+40.43%+114.24% 207B
Average +1.11%-1.54%+40.41%+76.99% 464.42B
Weighted average by Cap. +1.22%-1.96%+42.52%+86.69%

Financials

2026 *2027 *
Net sales 26B 3.88B 3.48B 3.18B 2.9B 5.47B 364B 5.64B 38.31B 15.27B 194B 14.55B 14.24B 614B 26.29B 3.92B 3.52B 3.21B 2.93B 5.53B 369B 5.7B 38.73B 15.45B 197B 14.72B 14.4B 621B
Net income 4.62B 689M 618M 565M 516M 971M 64.77B 1B 6.81B 2.71B 34.56B 2.59B 2.53B 109B 4.67B 696M 625M 571M 521M 982M 65.47B 1.01B 6.88B 2.74B 34.93B 2.61B 2.56B 110B
Net Debt 3.93B 586M 526M 481M 439M 827M 55.11B 853M 5.79B 2.31B 29.41B 2.2B 2.15B 92.83B -218M -32.52M -29.17M -26.66M -24.33M -45.84M -3.06B -47.29M -321M -128M -1.63B -122M -119M -5.15B
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
26-11-09 DKK 52.70 +2.13% 22,207
26-11-06 DKK 51.60 +1.18% 20,747
26-11-05 DKK 51.00 +0.79% 35,614
26-11-04 DKK 50.60 +1.20% 59,052
26-11-03 DKK 50.00 +0.81% 30,559
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
56.00DKK
Average target price
50.12DKK
Spread / Average Target
-10.49%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck